Imidazo[2,1-b][1,3,4]thiadiazole is a promising scaffold for developing optoelectronic materials. In this study, 12 imidazo[2,1-b][1,3,4]thiadiazole derivatives (ITDs) with an A-π1-π2-π3-D architecture have been computationally designed by incorporating four electron-withdrawing diazenyl-thiadiazole groups (R1) with varying numbers of cyano groups and three electron-donating groups (R2), namely pyrene, phenoxazine and diethylamino groups. Their optoelectronic and nonlinear optical (NLO) properties have been investigated computationally at the CAM-B3LYP/6-31++G(d,p) level in chloroform. ITD3d has exhibited the lowest HOMO–LUMO energy gap of 3.25 eV and a red shift of 202 nm in its simulated UV–visible absorption maximum compared with the parent molecule. The diethylamino and 2-(tricyanoethenyl)-5-diazenyl-1,3,4-thiadiazole group have efficiently enhanced the absorption maximum. ITD1d has shown the highest mean linear polarisability <α> in the gas phase and solvent phases, at 106.52 × 10−24 esu and 128.73 × 10−24 esu, respectively. ITD3d has exhibited the highest first-order hyperpolarisability (βtotal) of 957.82 × 10−30 esu and 1243.73 × 10−30 esu and mean second-order hyperpolarisability <γ> of 6.83 × 10−33 esu and 11.19 × 10−33 esu in the gas phase and solvent phases, respectively. These findings highlight the potential of the designed ITDs as NLO materials.
No takes yet. Share an insight, caveat, or question.
Sridhar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: